NovoCure Ltd. ( (NVCR) ) has released its Q3 earnings. Here is a breakdown of the information NovoCure Ltd. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novocure Ltd. is a global oncology company specializing in the development and commercialization of Tumor Treating Fields (TTFields) therapy, aimed at extending survival in patients with aggressive forms of cancer.
In its third-quarter 2025 financial report, Novocure announced a revenue increase of 8% year-over-year, reaching $167 million, driven by growth in active patient numbers and favorable exchange rates. The company also highlighted significant progress in its clinical and product development pipelines, including a premarket approval application for TTFields therapy in pancreatic cancer under review by the FDA.
Key financial metrics for the quarter included a gross margin of 73%, down from 77% the previous year, primarily due to costs associated with new product rollouts and increased tariffs. Research and development expenses rose by 4% to $54 million, while sales and marketing expenses saw a slight decrease. The company reported a net loss of $37.3 million, with a loss per share of $0.33, and an adjusted EBITDA of negative $3 million. Despite these challenges, Novocure maintains a strong cash position with over $1 billion in cash and short-term investments.
Operationally, Novocure reported 4,416 active patients on TTFields therapy globally, with significant contributions from the U.S., Germany, France, and Japan. The company also achieved regulatory milestones, including the acceptance of its PMA application for pancreatic cancer treatment and coverage approval for Optune Gio in Spain.
Looking ahead, Novocure remains focused on expanding its market presence and achieving profitability. The company anticipates submitting further regulatory applications and expects data readouts from ongoing clinical trials in the coming quarters, positioning itself as a leading platform therapy company by the end of 2026.